To describe the baseline Demographic data characterisics of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
Demographic data
1. Mean age at the inclusion into the study, and age groups (\<50; 50-65, \>65 years);
2. Mean age at the primary COPD diagnosis;
3. Proportion of men and women;
4. Proportion of patients with each educational status (higher, secondary special, secondary general) at inclusion;
5. Proportion of patients from each residential region of Russia;
To describe the baseline Negative lifestyle factors characterisics of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
Negative lifestyle factors 6. Proportion of patients with negative lifestyle factors at inclusion (evaluated on Visit 1 based on patient's interview):
a. Proportion of patients with history of smoking (former smoker)/current smokers - applicable for tobacco and e-cigarettes (vapes) smoking; d. Proportion of patients with overeating; e. Proportion of patient with physical inactivity.
To describe the baseline Anthropometry data characterisics of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
Anthropometry data 7. Mean body mass index (BMI) at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1);
To describe the baseline COPD drug treatment duration in previous 52 weeks of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
9\. Proportion of patients receiving different classes of drugs for treatment of COPD during prior 52 weeks before inclusion. The following classes of drug or their combinations will be collected. The combinations may be prescribed as separate drugs or fixed combination (of ≥1 drug class in one medication):
1. SABA alone;
2. ICS alone
3. LABA alone
4. LAMA alone
5. LABA and LAMA
6. ICS and LABA
7. ICS and LAMA
8. LABA and LAMA plus:
a) Macrolide antibiotics b) CS
To describe the baseline Cardiovascular diseases of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
Cardiovascular diseases 10. Proportion of patients with cardiovascular diseases (heart failure; ischaemic heart disease; myocardial infarction; arrhythmia; stroke; arterial hypertension; peripheral arterial disease; diabetes mellitus (type I, type II); chronic kidney disease (CKD); pulmonary hypertension) at inclusion (diagnosed in medical documentation ever or identified on the Visit 1 via a patient interview);
To describe the baseline other comorbidities of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
Other comorbidities 11. Proportion of patients with atrial fibrillation/flutter, ventricular arrhythmias, other arrhythmia (be calculated in patients with presence of arrhythmia before or on Visit 1); 18. Proportion of patients with different other comorbidities at inclusion (diagnosed in previous 52 weeks or on Visit 1).
To describe the baseline Blood eosinophils count of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
Blood eosinophils count 19. Mean blood eosinophils count (cells/μl) at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1); 20. Proportion of patients with different levels of blood eosinophils count at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1):
1. \<150 cells/μl;
2. ≥150 cells/μl;
3. ≥300 cells/μl.
To describe the baseline mean smoking index .
52 weeks of retrospective data before visit 1
applicable for current/former tobacco smokers (pack-years)
To describe the baseline mean duration of smoking
52 weeks of retrospective data before visit 1
applicable for current/former e-cigarettes (vapes) smokers (years);
To describe the Proportion of patients with overweight
52 weeks of retrospective data before visit 1
determined as BMI ≥25 kg/m2 at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1
To describe the baseline dosages of COPD drug treatment in previous 52 weeks of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
Proportion of patients receiving different classes of drugs for treatment of COPD. The following classes of drug or their combinations will be collected. The combinations may be prescribed as separate drugs or fixed combination (of ≥1 drug class in one medication):
1. dosage SABA alone ;
2. dosage ICS alone
3. dosage LABA alone
4. dosage LAMA alone
5. dosage LABA and LAMA
6. dosage ICS and LABA
7. dosage ICS and LAMA
8. LABA and LAMA plus:
a) dosage Macrolide antibiotics b) dosage CS
To describe the baseline proportion of patients with heart failure of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
12\. Proportion of patients will be evaluated for each heart failure phenotype based on LVEF - HFrEF, HFmrEF, HFpEF (to be calculated in patients with presence of heart failure before or on Visit 1);
To describe the baseline data of LVEF of patients with heart failure of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
13\. Mean and median value of LVEF, % (to be calculated in patients with presence of heart failure before or on Visit 1 and available data on LVEF based on echocardiography);
To describe the baseline proportion of patients with each CKD stage - C1, C2, C3a, C3b, C4, C5 of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
14\. to be calculated in patients with presence of CKD before or on Visit 1.
To describe the baseline mean office BP (SBP and DBP) measured at Visit 1 of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
15\. this parameter evaluated in total population and in patients with presence of AH before or on Visit 1)
To describe the baseline proportion of patients with AH by distribution by AH stage (I, II, III), AH degree (1st, 2nd, 3rd) and risk category at Visit 1 of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
16\. to be evaluated in patients with presence of AH before or on Visit 1;
To describe the baseline proportion of patients with various classes of medications used for treatment of CVD of outpatients with moderate and severe COPD.
52 weeks of retrospective data before visit 1
17\. to be evaluated in patients with at least one cardiovascular disease